The Latest Cardiac and Vascular News
Joshua Ziel, PhD, appointed as Chief Operating Officer and interim Chief Executive Officer Gary Burgess, MD, appointed as Chief Medical Officer Sarah Fritchley, PhD, appointed as Senior Vice President, Clinical Development and Operations DURHAM, N.C., June 01, 2023 (GLOBE NEWSWIRE) […]
Expansion of the AER-901 development program to include pulmonary hypertension associated with interstitial lung disease (PH-ILD) builds on the company’s existing program in pulmonary arterial hypertension (PAH) PH-ILD shares clinical and pathophysiological features with PAH, however, there is only one […]
AER-901 (inhaled imatinib), a potential reverse-remodeling therapy, is being developed to address unmet need for PAH treatments that target pulmonary vascular remodeling while supporting ease-of-use for patients. PAH is a rare and progressive disease with no cure; pulmonary vascular remodeling […]
DURHAM, N.C., June 16, 2022 (GLOBE NEWSWIRE) — Aerami Therapeutics, Inc. (the “Company”), a biopharmaceutical company focused on developing inhaled therapies to treat severe respiratory and other chronic diseases, today announces the appointment of Lisa Yañez as chief operating officer. Ms. Yañez brings […]
Pulmonary arterial hypertension (PAH) affects almost 68,000 patients worldwide, with treatment limited to vasodilators, none of which are disease-modifying Dosing of patients in Phase 1 trial is currently ongoing Plans to enter Phase 2/3 Trials in early 2022 DURHAM, N.C., […]
Pulmonary arterial hypertension (PAH) affects almost 68,000 patients worldwide, with treatment limited to vasodilators, none of which are disease-modifying Dosing of patients in Phase 1 trial is currently ongoing with results expected later this year Plans to enter Phase 2/3 […]
